BriaCell Therapeutics Corp. Warrant expiring 2031

Company Overview

Business Model: BRIACELL THERAPEUTICS CORP. is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care. The Company's core value proposition lies in harnessing the body's own immune system to recognize and destroy cancer cells. Its primary revenue generation mechanism is anticipated to be through the commercialization of its therapeutic candidates, following successful clinical development and regulatory approval. The lead candidate, Bria-IMT™, is a targeted immunotherapy currently in a pivotal Phase 3 study for metastatic breast cancer in combination with an immune checkpoint inhibitor. BRIACELL THERAPEUTICS CORP. is also advancing personalized off-the-shelf immunotherapies, Bria-OTS™ and Bria-OTS+™, for various cancer types, and a soluble CD80 protein therapeutic. The Company operates as a pre-revenue entity, with its business model centered on research, development, and eventual commercialization.

Market Position: The global market for cancer drugs, including immunotherapy, is projected to reach nearly $441 billion by the end of 2029. In the United States, approximately 319,750 people are estimated to be diagnosed with breast cancer in 2025, with over 42,170 projected to die. Metastatic breast cancer (MBC) affects a significant and growing patient population, with over 150,000 women living with MBC in the US in 2015, projected to increase to over 240,000 by 2030. For patients with metastatic disease at diagnosis, the 5-year survival rate is 30%. Current therapeutic options for MBC, particularly in second or higher lines of therapy, offer limited effectiveness, with reported overall response rates (ORR) ranging from 3-5%, progression-free survival (PFS) from 1.6 to 2.3 months, and overall survival (OS) from approximately 7 to 14 months. BRIACELL THERAPEUTICS CORP. positions Bria-IMT™ to address this unmet medical need, having reported benchmark-beating median overall survival of 13.4 months in its Phase 2 study of Bria-IMT™ combination with retifanlimab in MBC patients, and 16.5 months for patients treated with the Phase 3 formulation since 2022. The Company also reported superior median overall survival for Bria-IMT™ plus CPI in hormone receptor positive (HR+) MBC patients (17.3 months) and triple-negative breast cancer (TNBC) patients (13.9 months) compared to TRODELVY® (14.4 months for HR+, 11.8 months for TNBC) and single-agent chemotherapy (11.3 months for HR+, 6.9 months for TNBC).

Recent Strategic Developments:

• Pivotal Phase 3 Study for Bria-IMT™: BRIACELL THERAPEUTICS CORP. is advancing its Bria-IMT™ targeted immunotherapy in combination with retifanlimab (an immune checkpoint inhibitor manufactured by Incyte) in a pivotal Phase 3 study (NCT06072612) for metastatic breast cancer. Bria-IMT™ holds Fast Track Designation from the U.S. Food and Drug Administration (the "FDA"). As of April 22, 2025, over 100 patients have been consented and over 75 enrolled. Top-line data is anticipated as early as H1-2026. The Data Safety Monitoring Board (DSMB) completed its first, second, and third safety reviews on December 2, 2024, March 20, 2025, and June 24, 2025, respectively, recommending continuation of the study with no safety concerns.
• Bria-OTS™ Clinical Advancement: The Phase 1/2 study of Bria-OTS™ (NCT06471673) in metastatic breast cancer is ongoing. The first patient treated with Bria-OTS™ as a single agent demonstrated complete resolution of a lung metastasis, confirmed at 4 and 6 months follow-up. The study cleared safety evaluation for monotherapy and has transitioned to dosing patients in combination with an immune checkpoint inhibitor (tislelizumab® manufactured and supplied by BeiOne, Ltd.).
• Next-Generation Candidates: BRIACELL THERAPEUTICS CORP. is advancing Bria-PROS+™ (for prostate cancer) and Bria-BRES+™ (for breast cancer). In September 2024, the Company received positive feedback from its Pre-Investigational New Drug Application (Pre-IND) meeting with the FDA for Bria-PROS+™, with the FDA waiving requirements for animal toxicology and pharmacokinetic studies. Preclinical data for both Bria-PROS+™ and Bria-BRES+™ showing in vitro anti-cancer activity were presented at the SITC Annual Meeting in November 2024.
• BriaPro Therapeutics Corp. Spin-out and Antibody Development: On August 31, 2023, BRIACELL THERAPEUTICS CORP. completed a plan of arrangement spin-out of certain pipeline assets, including Bria-TILsRx™ and protein kinase C delta (PKCδ) inhibitors, to BriaPro Therapeutics Corp., a two-thirds majority-owned subsidiary. BriaPro Therapeutics Corp. is developing high-affinity antibodies against B7-H3, an immune checkpoint molecule, leveraging molecular modeling and backed by provisional U.S. patent filings. The antibodies are intended for incorporation into the proprietary Bria-TILsRx™ platform, designed to activate tumor-infiltrating lymphocytes. On July 29, 2025, BriaPro Therapeutics Corp. filed a patent application for its immuno-oncology platform with novel multitargeting agents.
• Financings and Share Consolidations: During the fiscal year ended July 31, 2025, BRIACELL THERAPEUTICS CORP. raised approximately $50.9 million in gross proceeds from equity financings. The Company effected two reverse stock splits: one on January 24, 2025 (1-for-15) and another on August 25, 2025 (1-for-10).

Geographic Footprint: BRIACELL THERAPEUTICS CORP. maintains corporate offices in West Vancouver, British Columbia, Canada, and corporate and research offices in Philadelphia, Pennsylvania, United States. Its clinical trials for Bria-IMT™ are conducted at multiple sites throughout the United States. The Company has employees located in various US states (NY, FL, PA, SC, NV, NJ), Canada, and Israel. Intellectual property protection is sought in the U.S. and internationally, with patents granted in Japan, Australia, New Zealand, and the US.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: N/A (pre-revenue)
• Operating Margin: N/A (pre-revenue)
• Net Margin: N/A (pre-revenue)

Investment in Growth:

• R&D Expenditure: $21,270,678 (FY2025) vs. $27,177,807 (FY2024). The decrease was primarily driven by lower clinical trial sites and investigational drug costs, which declined from $20,885,903 in 2024 to $14,765,112 in 2025, reflecting the conclusion of the Bria-IMT™ Phase 1/2a trial and a focus on optimizing expenditures for the pivotal Phase 3 trial. Wages and salaries increased from $4,567,307 in 2024 to $5,356,806 in 2025.
• Capital Expenditures: $0 (FY2025) vs. $456,801 (FY2024) for laboratory equipment.
• Strategic Investments:
  • Equity investment in BC Therapeutics, Inc.: $330,000 (FY2025) vs. $225,000 (FY2024). The total equity investment in BC Therapeutics, Inc. was $524,278 as of July 31, 2025, representing a 63.1% ownership interest.

Business Segment Analysis

BRIACELL THERAPEUTICS CORP. has one operating segment and reports its results as a single operating segment.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: None disclosed.
• Dividend Payments: BRIACELL THERAPEUTICS CORP. has not paid cash dividends to date and does not anticipate paying any in the foreseeable future, as it intends to retain future earnings to fund the development and growth of its business.
• Dividend Yield: N/A
• Future Capital Return Commitments: None disclosed.

Balance Sheet Position:

• Cash and Equivalents: $10,493,808 (July 31, 2025) vs. $862,089 (July 31, 2024)
• Total Debt: No significant debt is disclosed on the balance sheet.
• Net Cash Position: As of July 31, 2025, the Company had cash and cash equivalents of $10,493,808 and short-term investments of $7,372,473, against total current liabilities of $3,977,988 and a non-current warrant liability of $337,672.
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Not applicable as no significant debt is disclosed.

Cash Flow Generation:

• Operating Cash Flow: $(28,170,520) (FY2025) vs. $(24,126,128) (FY2024)
• Free Cash Flow: Not explicitly calculated, but negative given operating cash flow and capital expenditures.
• Cash Conversion Metrics: Not disclosed.

Operational Excellence

Production & Service Model: BRIACELL THERAPEUTICS CORP. does not own or operate manufacturing facilities for its product candidates and relies entirely on third-party contract manufacturers for raw materials, active pharmaceutical ingredients, and finished product candidates for its clinical trials. The manufacturing process for Bria-IMT™ involves growing cells in tissue culture media, irradiating them, and then cryopreserving them for stockpiling and direct shipment to clinical sites for inoculation. Each lot of Bria-IMT™ undergoes testing for potency (GM-CSF production), identity (HER2+ and ER/PR-), and absence of infectious agents.

Supply Chain Architecture: Key Suppliers & Partners:

• Manufacturing Partners:
  • UC Davis: Manufactures Bria-IMT™ at its GMP facility.
  • FujiFilm Diosynth Biotechnology ("Fuji"): Manufactures Bria-IMT™ for anticipated use in clinical studies, including the Phase 3 study.
  • Waisman Biomanufacturing at the University of Wisconsin-Madison ("Waisman"): Manufactures Bria-Pros™ for anticipated use in clinical studies.
• Clinical Research Organization: Prevail InfoWorks, Inc. ("InfoWorks"): Provides comprehensive clinical services and technologies, including clinical site coordination, project management, clinical monitoring, pharmacovigilance (safety management), and an integrated real-time data analytics platform (The Single Interface®) for the pivotal Phase 3 study.
• Immune Checkpoint Inhibitor Suppliers:
  • Incyte: Manufactures retifanlimab, an anti-PD1 antibody used in Bria-IMT™ combination studies.
  • Merck & Co., Inc.: Manufactures pembrolizumab (KEYTRUDA®), an immune checkpoint inhibitor used in earlier Bria-IMT™ combination studies.
  • BeiOne, Ltd.: Manufactures and supplies tislelizumab® for Bria-OTS™ combination studies.

Facility Network:

• Corporate Offices: Suite 300, Bellevue Centre, 235-15th Street, West Vancouver, British Columbia, Canada.
• Corporate and Research Offices: 2929 Arch Street 3rd Floor, Philadelphia, Pennsylvania, United States. As of August 2025, the Company commenced a month-to-month lease arrangement for this space at approximately $43,000 per month.
• Manufacturing: Production is outsourced to UC Davis GMP facility, FujiFilm Diosynth Biotechnology in Thousand Oaks, California, and Waisman Biomanufacturing at the University of Wisconsin-Madison.
• Research & Development: Conducted at the Philadelphia office and through collaborations.

Operational Metrics: No specific operational metrics such as capacity utilization, efficiency measures, or quality indicators are explicitly disclosed beyond clinical trial progress.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: The Company plans to develop clinical data for Bria-IMT™ and use this information to reach out directly to oncologists.
• Physician Education: A physician education campaign will target oncologists most likely to treat metastatic breast cancer, focusing on Bria-IMT™ data and its optimal use in combination with other therapies.
• Channel Partners: BRIACELL THERAPEUTICS CORP. intends to pursue partnerships with other pharmaceutical companies to market its drugs, aiming to leverage established presences in the oncology space.

Customer Portfolio:

• Enterprise Customers: Not applicable as the Company is pre-revenue.
• Strategic Partnerships: Collaborations with pharmaceutical companies (e.g., Incyte, Merck & Co., Inc., BeiOne, Ltd.) for immune checkpoint inhibitors in combination therapies.
• Customer Concentration: Not applicable as the Company is pre-revenue.

Geographic Revenue Distribution: Not applicable as BRIACELL THERAPEUTICS CORP. is a pre-revenue company.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The cancer drug market, including immunotherapy, is a significant and growing sector, projected to reach nearly $441 billion by 2029. It is characterized by high unmet medical needs, particularly for late-stage metastatic breast cancer patients who have failed multiple prior therapies, where current response rates and survival outcomes are poor. The industry involves extensive governmental regulation for research, development, testing, manufacturing, and commercialization. Competition is intense, with both large pharmaceutical companies and smaller niche players. Mergers and acquisitions are common, leading to resource concentration.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Large Pharmaceutical Companies: Bristol-Myers Squib Company, Merck & Co., Inc., Genentech, Inc. (a subsidiary of Roche Holding AG), AstraZeneca PLC, Celgene Corporation, Johnson & Johnson/Janssen Pharmaceuticals, Amgen, Novartis, Acerta Pharmaceuticals (a subsidiary of AstraZeneca), Juno Therapeutics, Inc. (a subsidiary of Celgene), Kite Pharma, Inc. (a wholly-owned subsidiary of Gilead Sciences, Inc.), and Pfizer, Inc./EMD Serono, Inc. These companies possess substantially greater financial, technical, and human resources, as well as extensive experience in obtaining regulatory approvals and commercializing treatments.
• Cancer Vaccine Developers: Marker Therapeutics, Inc. (TPIV200), Antigen Express (AE-37), Merck KgA (Stimuvax).
• Targeted Therapy Developers: Roche/Genentech (trastuzumab (HERCEPTIN), pertuzumab (PERJETA), atezolizumab (TECENTRIQ)), Celgene (nab-paclitaxel (ABRAXANE)).
• Other Immunotherapy Approaches: Numerous biotech companies are developing peptide cocktails, triple peptide regimens, recombinant HER2, antigen-pulsed dendritic cells, DNA immunogens, whole cell allogeneic GM-CSF secreting SKBR3 or T47D cells, HLA-A2/A3-restricted immunogenic peptides, oxidized mannan-MUC1, and personalized peptide immunogens.

Emerging Competitive Threats: New entrants, disruptive technologies, and alternative solutions, particularly those combining targeted immunotherapies with checkpoint inhibitors, pose ongoing competitive threats.

Competitive Response Strategy: BRIACELL THERAPEUTICS CORP. aims to maintain competitive advantage by developing robust clinical data for Bria-IMT™ to demonstrate its potential for long-term remission and improved survival rates in late-stage MBC. The Company plans physician education campaigns and intends to pursue partnerships with other pharmaceutical companies for marketing and distribution to broaden market access.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics: The anticipated market for BRIACELL THERAPEUTICS CORP.'s potential products and technologies is unproven and may not expand as expected due to competition from other products or issues with commercial viability. The Company faces intense competition from larger, more resourced pharmaceutical and biotechnology companies. Technology Disruption: Pre-clinical studies and initial clinical trials are not necessarily predictive of future results. Favorable outcomes in early trials may not be replicated in later-stage trials, which could lead to delays, repetition, or termination of product development. Customer Concentration: Not applicable as the Company is pre-revenue and does not have a customer base.

Operational & Execution Risks

Supply Chain Vulnerabilities: BRIACELL THERAPEUTICS CORP. is heavily reliant on third-party contract manufacturers for all raw materials, active pharmaceutical ingredients, and finished product candidates for its clinical trials. Any failure by these third parties to meet supply requirements, quality standards, or timelines could materially and adversely affect product development and commercialization. Supplier Dependency: The Company depends significantly on third-party consultants and contractors, including contract research organizations, medical institutions, clinical investigators, and contract laboratories, to manage and conduct its multi-center clinical trials and product development. Delays or failures in performance by these third parties could extend, delay, suspend, or terminate clinical trials. Geographic Concentration: The Company's international operations expose it to risks inherent in foreign jurisdictions, including country-specific taxation policies, imposition of additional foreign government controls, export license requirements, changes in tariffs and other trade restrictions, and complexities in collecting receivables. Capacity Constraints: While not explicitly detailed as a risk, reliance on third-party manufacturers implies potential for capacity constraints if demand for products grows significantly post-approval. Key Personnel Dependency: BRIACELL THERAPEUTICS CORP. is highly dependent on the services of a few key personnel, including Dr. William V. Williams (President, Chief Executive Officer, and Director), Dr. Giuseppe Del Priore (Chief Medical Officer), and Dr. Miguel A. Lopez-Lago (Chief Scientific Officer). The loss of any of these individuals, or the inability to attract and retain qualified personnel, could materially and adversely affect the business. Data Security Breaches: The Company and its third-party vendors are susceptible to cybersecurity threats and security incidents, including attempts to gain unauthorized access to confidential data. A successful cybersecurity attack could compromise confidential information, disrupt business operations, expose the Company to liability, and damage its reputation.

Financial & Regulatory Risks

Market & Financial Risks:

• Going Concern: There is substantial doubt about BRIACELL THERAPEUTICS CORP.'s ability to continue as a going concern, evidenced by significant accumulated losses ($111,755,564 as of July 31, 2025) and negative cash flows from operating activities. The Company's continuation is dependent upon its ability to generate positive cash flows from operations and to secure additional equity and/or debt financing.
• Capital Requirements: The Company anticipates requiring additional capital to complete its current research and development programs, prepare for market approval, and successfully launch products. Failure to obtain adequate financing on acceptable terms could result in delays or indefinite postponement of further research and development.
• Dilution: Future equity financings are likely to dilute the interests of existing shareholders.
• Share Price Volatility: The market price of the Company's securities may be highly volatile due to factors beyond its control, including changes in financial estimates, industry trends, and activities of short sellers.
• PFIC Status: BRIACELL THERAPEUTICS CORP. believes it will be classified as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes for the taxable year ending July 31, 2025, and possibly succeeding years, which could result in adverse tax consequences for U.S. shareholders. Regulatory & Compliance Risks:
• Regulatory Approval: The Company has not yet marketed, distributed, or sold an approved product. There is a risk of not obtaining U.S., Canadian, and/or foreign regulatory approval for its product candidates in a timely manner or at all. Modifications to product candidates may require new regulatory clearances or approvals, potentially leading to recalls or cessation of marketing.
• Adverse Side Effects: Clinical trials may fail to demonstrate that product candidates are safe and effective for proposed indicated uses, or may result in the discovery of unforeseen adverse side effects.
• Price Controls & Reimbursement: Sales of pharmaceutical products are significantly dependent on third-party coverage and reimbursement. The Company is subject to increasing government price controls and other restrictions on pricing, reimbursement, and access to drugs, which could adversely affect future revenues and profitability.
• Privacy Laws: The Company is subject to U.S. federal and state privacy laws (e.g., HIPAA, HITECH) and equivalent laws in other nations, which may increase operational costs and expose it to civil and criminal sanctions for non-compliance.
• Anti-Kickback Statute & False Claims Act: The Company's future financial relationships with healthcare providers and purchasers will be governed by the federal Anti-Kickback Statute and False Claims Act, and similar state and foreign laws. Violations could result in substantial criminal, civil, or administrative penalties and exclusion from federally funded healthcare programs.
• Export Controls: International operations are subject to export license requirements and changes in trade restrictions. Compliance with sanctions and export controls is required.

Geopolitical & External Risks

Geopolitical Exposure: Global economic uncertainty and financial market volatility caused by political instability, changes in international trade relationships, and conflicts (e.g., Russia-Ukraine, Middle East tensions) could make it more difficult for the Company to access financing, disrupt global supply chains, and adversely affect its business and operations. Trade Relations: Government actions, including sanctions, export controls, tariffs, or other trade restrictions, could disrupt global supply chains and trade flows, exacerbating inflationary or recessionary pressures. Sanctions & Export Controls: Compliance requirements and business limitations due to sanctions and export controls. Inflation: Inflation has the potential to adversely affect the Company's business, results of operations, financial position, and liquidity by increasing its overall cost structure, particularly if it is unable to achieve commensurate increases in the prices it charges its customers.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Immunotherapies: Developing novel immunotherapies to harness the body’s immune system against cancer.
• Whole-Cell Immunotherapy: Lead candidate Bria-IMT™ (SV-BR-1-GM) is a genetically engineered human breast cancer cell line designed to secrete GM-CSF, a factor that stimulates dendritic cells and T cells.
• Personalized Off-the-Shelf Immunotherapy: Bria-OTS™ and Bria-OTS+™ are engineered to express 15 unique HLA types, providing matched treatment to over 99% of the population via a simple saliva test.
• Next-Generation Candidates: Bria-PROS+™ (for prostate cancer) and Bria-BRES+™ (for breast cancer) are advanced forms.
• Antibody Therapeutics: BriaPro Therapeutics Corp. (majority-owned subsidiary) is developing high-affinity antibodies directed against B7-H3, an immune checkpoint molecule, for incorporation into the Bria-TILsRx™ platform.
• Soluble CD80 (sCD80): Exclusive license from University of Maryland, Baltimore County to develop and commercialize sCD80 as a biologic agent for cancer treatment, acting as both an immune system stimulator and immune checkpoint inhibitor. Innovation Pipeline:
• Bria-IMT™: Pivotal Phase 3 study in metastatic breast cancer (NCT06072612) in combination with retifanlimab.
• Bria-OTS™: Phase 1/2 study in metastatic breast cancer (NCT06471673) as monotherapy and in combination with tislelizumab®.
• Bria-PROS+™: Pre-IND meeting with FDA for prostate cancer, with animal toxicology and pharmacokinetic studies waived, simplifying the development pathway.
• Bria-TILsRx™ Platform: Developing multivalent technology for simultaneous engagement of multiple cancer-associated and immune pathway targets, with the goal of enhancing anti-tumor immune responses and selectively blocking inhibitory signals. Early agents include antibodies to B7-H3.

Intellectual Property Portfolio:

• Patent Strategy: BRIACELL THERAPEUTICS CORP. seeks patent protection in the U.S. and internationally for its product candidates and technologies, relying on combinations of patent applications and trade secret protection.
• Bria-IMT™: U.S. Patent No. 7,674,456 B2, issued March 9, 2010, covers compositions comprising SV-BR cells and therapeutic methods of use, expiring May 31, 2028, with potential for a 5-year patent term extension.
• Bria-OTS™: International patent application (PCT/US2017/019757) has been granted in Japan (JP Patent No. 6901505, extends to February 27, 2037), Australia (AU Patent No. 2017224232, extends to February 27, 2037), New Zealand (NZ Patent No. 745327, extends to February 27, 2037, and NZ Patent No. 785587, extends to February 27, 2037), and the US (US Patent No. 11,559,574 B2, extends to May 25, 2040). Another PCT application (PCT/US2023/014337) for Bria-OTS™ expressing co-stimulatory molecules and immunomodulatory cytokines entered National Phase in the second half of 2024.
• Dendritic Cells: BRIACELL THERAPEUTICS CORP. and the National Cancer Institute (NCI) co-filed an international patent application under the PCT directed to engineered mammalian dendritic cells that express exogenous MHC class II alleles.
• Soluble CD80: Exclusive license from University of Maryland, Baltimore County for USPN 8,956,619 B2, USPN 9,650,429 B2, and USPN 10,377,810 B2.
• BriaPro Therapeutics Corp.: Provisional U.S. patent filings for high-affinity antibodies directed against B7-H3, with international filings anticipated. Filed a patent application for its immuno-oncology platform with novel multitargeting agents on July 29, 2025.

Technology Partnerships:

• National Cancer Institute (NCI): Ongoing collaboration to investigate Bria-OTS™ and co-filed an international patent application for engineered mammalian dendritic cells.
• University of Maryland, Baltimore County (UMBC): Exclusive license agreement for Soluble CD80.
• ImmunoPrecise Antibodies and Receptor AI: Collaborating with BriaPro Therapeutics Corp. to identify drug candidates using artificial intelligence.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The Board has not adopted director term limits or other automatic mechanisms of Board renewal. The nominating and corporate governance committee is responsible for developing a skills and competencies matrix for the Board and individual directors, and for assessing the effectiveness and contribution of the Board, each committee, and each director.

Board Composition: The Board is currently comprised of seven directors. Five of the seven members are considered "independent" as defined under the Nasdaq Rules: Dr. Jane A. Gross, Dr. Rebecca Taub, Mr. Jamieson Bondarenko, Mr. Vaughn C. Embro-Pantalony, and Mr. Martin E. Schmieg. Dr. William V. Williams is not independent due to his role as Chief Executive Officer. Mr. Jamieson Bondarenko serves as Chairman of the Board. The Board has an Audit Committee, a Compensation Committee, and a Nominating and Corporate Governance Committee, each operating under a written charter.

Human Capital Strategy

Workforce Composition:

• Total Employees: As of October 15, 2025, BRIACELL THERAPEUTICS CORP. had 22 full-time employees. The average number of employees for the fiscal year ended July 31, 2025, was 20, of whom four were executive management.
• Geographic Distribution: Employees are located in various US states (NY, FL, PA, SC, NV, NJ), Canada, and Israel.
• Skill Mix: Not explicitly detailed, but the Company's focus on biotechnology and clinical development implies a workforce with strong scientific, clinical, and corporate functional competencies.

Talent Management: Acquisition & Retention:

• Hiring Strategy: Anticipated growth in all areas of the business (research and development, clinical operations, regulatory compliance, manufacturing, and corporate functions) is expected to require attracting, retaining, training, and motivating additional qualified personnel.
• Retention Metrics: Not disclosed.
• Employee Value Proposition: Certain officers have indicated their willingness to receive a portion of their compensation in shares of the Company, subject to applicable Nasdaq rules. Directors and officers agreed to defer payment of their fees/compensation until a financing was completed in calendar year 2025.

Diversity & Development:

• Diversity Metrics: Not disclosed.
• Development Programs: The nominating and corporate governance committee is responsible for coordinating orientation and continuing director development programs. The Chairman of the Board oversees director continuing education designed to maintain or enhance skills and understanding of the business.
• Culture & Engagement: The Board has adopted a Code of Ethics applicable to all directors, officers, and employees, and a whistleblowing policy to facilitate confidential, anonymous submissions of complaints without fear of retaliation.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• FDA Regulation: BRIACELL THERAPEUTICS CORP. is subject to extensive regulation by the FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign countries. This regulation covers research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring, and reporting of biologics.
• Approval Process: The process involves preclinical studies, submission of an Investigational New Drug Application (IND), approval by an independent Institutional Review Board (IRB), performance of adequate and well-controlled clinical trials (Phase 1, 2, 3), preparation and submission of a Biologics License Application (BLA), and satisfactory completion of FDA reviews and inspections.
• Accelerated Programs: Product candidates may be eligible for Fast Track designation (Bria-IMT™ currently holds this), Priority Review, and Breakthrough Therapy designation, which are designed to accelerate FDA review and approval for treatments addressing serious or life-threatening conditions with unmet medical needs.
• Other Healthcare Laws: The Company's activities are subject to compliance with the federal Anti-Kickback Statute, the Foreign Corrupt Practices Act, the False Claims Act (FCA), the Veterans Health Care Act, physician payment transparency laws, privacy laws (e.g., HIPAA, HITECH), and additional state laws similar to the foregoing.
• International Compliance: The Company is subject to various regulations in non-U.S. countries governing clinical trials, product licensing, pricing, and reimbursement. This includes requirements for Clinical Trial Applications (CTAs) in Europe and adherence to procedures like the centralized procedure or mutual recognition procedure for marketing authorization.

Trade & Export Controls:

• The Company's international operations expose it to export license requirements and changes in tariffs and other trade restrictions.
• Compliance with sanctions and export controls is required.

Legal Proceedings:

• There are no material legal proceedings pending against BRIACELL THERAPEUTICS CORP. The Company may be involved from time to time in ordinary litigation, negotiation, and settlement matters that are not expected to have a material effect on its operations or finances.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: For the fiscal years ended July 31, 2025 and 2024, BRIACELL THERAPEUTICS CORP. had no income tax expense due to its history of operating losses and valuation allowances. The reconciliation of the combined Canadian federal and provincial statutory income tax rate of 27% to the effective tax rate includes adjustments for tax rate changes, non-deductible expenses (e.g., share-based compensation), share issuance costs, adjustments for prior periods, R&D Credits, and valuation allowance.
• Geographic Tax Planning: The Company files income tax returns in the United States.
• Tax Reform Impact: Not explicitly detailed, but the Company accounts for income taxes by estimating future tax effects of temporary differences between financial reporting and tax bases of assets and liabilities, considering enacted tax rates and laws.
• Net Operating Loss (NOL) Carryforwards: As of July 31, 2025, the Company had US federal NOL carryforwards of approximately $40,450,000 (with expiry periods ranging between 2033 and indefinitely) and Canadian net operating loss carryovers of approximately $18,770,000 (with expiry periods ranging between 2035 and 2045).
• Uncertain Tax Positions: As of July 31, 2025, and 2024, no liability for unrecognized tax benefits was recorded, and no significant changes in unrecognized tax benefits are expected in the next 12 months.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: BRIACELL THERAPEUTICS CORP. maintains insurance policies relating to certain liabilities that its directors and officers may incur in such capacity. Cybersecurity coverage is incorporated into its insurance policies; however, there is no assurance that this insurance will cover all cybersecurity breaches or that policy limits will be sufficient to cover all related losses.
• Risk Transfer Mechanisms: Not explicitly detailed beyond insurance coverage.